GLP1R and type 2 diabetes mellitus: Overall, 26.8% of patients with T2D and comorbid CVD received DPP4i and not SGLT2i or GLP-1 RA, despite guideline recommendations at the time of prescription to use SGLT2i or GLP-1 RA due to CV benefits in this patient population.